Plumas Bancorp ( PLBC ) declares $0.33/share quarterly dividend , in line with previous. Forward yield 2.52% Payable May 15; for shareholders of record May 1; ex-div May 1. See PLBC Dividend Scorecard, Yield Chart, & Dividend Growth. More on Plumas Bancorp Seeking Alpha’s Quant Rating on Plumas Bancorp Historical earnings data for Plumas Bancorp Dividend scorecard for Plumas Bancorp Financial info...
Plumas Bancorp ( PLBC ) declares $0.33/share quarterly dividend , in line with previous. Forward yield 2.52% Payable May 15; for shareholders of record May 1; ex-div May 1. See PLBC Dividend Scorecard, Yield Chart, & Dividend Growth. More on Plumas Bancorp Seeking Alpha’s Quant Rating on Plumas Bancorp Historical earnings data for Plumas Bancorp Dividend scorecard for Plumas Bancorp Financial information for Plumas Bancorp
A censured lawyer using AI‑fabricated case law highlights how liability, trust, and auditability shape real enterprise AI adoption. Watch the video below to see why this may slow disruption and reshape which AI and data vendors ultimately win. *This video was published on April 14, 2026. Continue reading
A censured lawyer using AI‑fabricated case law highlights how liability, trust, and auditability shape real enterprise AI adoption. Watch the video below to see why this may slow disruption and reshape which AI and data vendors ultimately win. *This video was published on April 14, 2026. Continue reading
Archer Aviation (NYSE: ACHR) sits at the center of one of the most ambitious ideas in transportation: flying taxis. Its electric vertical takeoff and landing (eVTOL) aircraft aim to move passengers across cities in minutes, potentially transforming how people travel in congested urban areas. The opportunity is massive. Some estimates suggest urban air mobility could grow into a trillion-dollar mar...
Archer Aviation (NYSE: ACHR) sits at the center of one of the most ambitious ideas in transportation: flying taxis. Its electric vertical takeoff and landing (eVTOL) aircraft aim to move passengers across cities in minutes, potentially transforming how people travel in congested urban areas. The opportunity is massive. Some estimates suggest urban air mobility could grow into a trillion-dollar market over the coming decades. If that vision becomes reality, early leaders, like Archer, could benefit significantly. Most investors focus on the massive opportunity ahead. But they may be overlooking three key factors that could shape the stock returns over the next few years. Continue reading
FabrikaCr/iStock via Getty Images The last time I spoke about Climb Bio, Inc. ( CLYM ), it was with a Seeking Alpha article entitled " Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value ." Before going further on this biotech, it is important to highlight that in that article I mentioned that the company had acquired Tenet Medicines and also had obtained a $120 millio...
FabrikaCr/iStock via Getty Images The last time I spoke about Climb Bio, Inc. ( CLYM ), it was with a Seeking Alpha article entitled " Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value ." Before going further on this biotech, it is important to highlight that in that article I mentioned that the company had acquired Tenet Medicines and also had obtained a $120 million private placement agreement to carry it forward. The reason why I bring this up is because it decided to switch over its pipeline afterwards only to advance budoprutug [TNT119] and other drugs for the treatment of patients with autoimmune disorders. The end result is that it changed its name from Eliem Therapeutics to Climb Bio because of this strategic move on October 3, 2024. It has been a while since I updated this biotech, but at that time I had given it a Buy rating based on its potential to develop the use of its anti-CD19 monoclonal antibody [mAb] budoprutug for the treatment of patients with primary membranous nephropathy [pMN] in an ongoing phase 1b study. More about the clinical data below, but the company did end up actually releasing positive results from its phase 1b study using this drug to treat these autoimmune disorder patients. Even better, it is currently in the process of evaluating the use of budoprutug in the ongoing phase 2 PrisMN trial treating these patients with pMN. Why do I believe it is important to go over this biotech now? That's because there are actually several catalysts or inflection points that are rapidly approaching. Initial data from the PrisMN trial is expected in the 2nd half of 2026. That's not all, either; this drug is also being explored in other studies targeting patients with Systemic Lupus Erythematosus [SLE] and immune thrombocytopenia [ITP] as well, with clinical readouts from both of these programs anticipated in the 2nd half of 2026 as well. Another item to mention is that budoprutug is versatile in the sense that the com...
It would be a mistake for the European Central Bank to signal where interest rates will be headed later this month, according to Governing Council member Joachim Nagel . Policymakers don’t yet have sufficient information whether a surge in energy costs will keep inflation high for longer — an outcome that would warrant a response, Nagel told reporters in Washington, where he’s attending the spring...
It would be a mistake for the European Central Bank to signal where interest rates will be headed later this month, according to Governing Council member Joachim Nagel . Policymakers don’t yet have sufficient information whether a surge in energy costs will keep inflation high for longer — an outcome that would warrant a response, Nagel told reporters in Washington, where he’s attending the spring meetings of the International Monetary Fund. A decision will be taken when the Governing Council meets in two weeks. “We need to keep our options open,” Nagel said. “It would be wrong to say things will go in the one or other direction. I’m not ready to pre-commit just yet.” The ECB is two weeks away from its next decision, and people familiar with internal discussions told Bloomberg that officials are leaning toward keeping the deposit rate unchanged at that time. Still, many have stressed that a hike shouldn’t be excluded in a quickly changing environment. Nagel said the German economy had a respectable start to the year but now faces weaker momentum due to the Iran war. Growth will probably be 0.3 percentage point weaker than previously projected, he added. In December, the Bundesbank predicted an expansion of 0.6% for the year. Mythos AI Sparks Fear and Confusion Among Global Finance Elite Markets Are Too Blasé on War’s Economic Toll, Policymakers Warn Anti-Recession Guardrails Are Weaker Than Ever Around the Globe German Finance Minister Lars Klingbeil said fighting in the Middle East will have a “massive impact on our growth and economic strength.” “We were all so happy — even if it was only modest growth — that we were back on track after four years without economic growth,” he said. “My response to that: We must do everything we can — through reforms, through the European process, which is why the E6 format is so important, and through structural decisions — to put the country back on a path to growth.” He highlighted that “this war in Iran is a significant setback...
Earnings Call Insights: ManpowerGroup (MAN) Q1 2026 Management View “Our Q1 results reflect disciplined execution and continued stabilization of revenue trends across key markets,” said Chairman & CEO Jonas Prising. “In the first quarter, we delivered reported revenues of $4.5 billion… organic constant currency growth of 3%… Systemwide revenue… was $5 billion.” Prising said management is “announci...
Earnings Call Insights: ManpowerGroup (MAN) Q1 2026 Management View “Our Q1 results reflect disciplined execution and continued stabilization of revenue trends across key markets,” said Chairman & CEO Jonas Prising. “In the first quarter, we delivered reported revenues of $4.5 billion… organic constant currency growth of 3%… Systemwide revenue… was $5 billion.” Prising said management is “announcing a transformation initiative that will reimagine how we operate… and provide significant cost optimization,” adding that the company “expect[s] will deliver $200 million in permanent cost savings in 2028,” alongside “evaluating opportunities to divest of non-core assets to strengthen our financial position.” Executive VP, CFO & Head of Investor Relations John McGinnis said, “Gross profit margin came in below the low-end of our guidance range driven by lower bench utilization in Europe and mix shifts impacting staffing margin,” while “as adjusted, EBITA was $61 million… EBITA margin was 1.4%.” President & Chief Strategy Officer Becky Frankiewicz said AI is “already driving measurable value,” including that in France, “our proprietary AI-Powered Sales Targeting Engine has generated approximately $200 million in incremental revenue,” and that with Hubert.ai, “we’ve completed over 25,000 AI-led interviews and reduced screening time by 67%.” Outlook McGinnis said, “we are forecasting earnings per share for the second quarter to be in the range of $0.91 to $1.01,” and added, “Our constant currency revenue guidance range is between a 1% increase and a 5% increase.” On profitability and taxes, McGinnis said, “EBITA margin for the second quarter is projected to be up 10 bps at the midpoint compared to the prior year,” and “we estimate that the effective tax rate for the second quarter will be 43%.” Versus the prior quarter’s tone on transformation planning, Q1 included a specific program scale-up: McGinnis said “we are excited to announce our path to expected savings of $200 milli...
ismagilov/iStock via Getty Images Neutral sentiment among individual investors about the short-term outlook for stocks increased in the latest AAII Sentiment Survey. Meanwhile, optimism and pessimism decreased. Bullish sentiment, expectations that stock prices will rise over the next six months, decreased 4.0 percentage points to 31.7%. Bullish sentiment is below its historical average of 37.5% fo...
ismagilov/iStock via Getty Images Neutral sentiment among individual investors about the short-term outlook for stocks increased in the latest AAII Sentiment Survey. Meanwhile, optimism and pessimism decreased. Bullish sentiment, expectations that stock prices will rise over the next six months, decreased 4.0 percentage points to 31.7%. Bullish sentiment is below its historical average of 37.5% for the ninth consecutive week. Neutral sentiment, expectations that stock prices will stay essentially unchanged over the next six months, increased 4.2 percentage points to 25.5%. Neutral sentiment is below its historical average of 31.5% for the 91st time in 93 weeks. Bearish sentiment, expectations that stock prices will fall over the next six months, decreased 0.2 percentage points to 42.8%. Bearish sentiment is unusually high and is above its historical average of 31.0% for the 10th consecutive week. The bull-bear spread (bullish minus bearish sentiment) decreased 3.8 percentage points to –11.1%. The bull-bear spread is below its historical average of 6.5% for the 10th consecutive week. This week’s special question asked AAII members if their inflation expectations have changed since the end of February. Here is how they responded: Yes, I expect inflation to be much higher: 19.3% Yes, I expect inflation to be moderately higher: 46.0% Yes, I expect inflation to be temporarily higher: 24.1% No, my inflation expectations are unchanged: 9.6% Not sure/no opinion: 0.5% This week’s Sentiment Survey results: Bullish: 31.7%, down 4.0 percentage points Neutral: 25.5%, up 4.2 percentage points Bearish: 42.8%, down 0.2 percentage points Historical averages: Bullish: 37.5% Neutral: 31.5% Bearish: 31.0% The AAII Sentiment Survey has been conducted weekly since July 1987.
(RTTNews) - Mortgage rates, or interest rates on home loans, continued to decline, falling to a four-week low, according to mortgage provider Freddie Mac.
(RTTNews) - Mortgage rates, or interest rates on home loans, continued to decline, falling to a four-week low, according to mortgage provider Freddie Mac.
Thieves believed to have escaped into sewers after holding staff and customers in Crédit Agricole branch for two hours Armed robbers held 25 people hostage at a bank in Naples for two hours on Thursday, before fleeing through a tunnel. The three thieves entered a branch of Crédit Agricole in the southern Italian city at about 11.30am, taking hostage staff and customers, who were freed by police a ...
Thieves believed to have escaped into sewers after holding staff and customers in Crédit Agricole branch for two hours Armed robbers held 25 people hostage at a bank in Naples for two hours on Thursday, before fleeing through a tunnel. The three thieves entered a branch of Crédit Agricole in the southern Italian city at about 11.30am, taking hostage staff and customers, who were freed by police a couple of hours later. Continue reading...
Valerii Apetroaiei/iStock via Getty Images Adagene Inc. ( ADAG ) is a clinical-stage oncology biotech that develops antibody-based immunotherapies. ADAG’s main asset is ADG126 (muzastotug), which uses its masking technology (SAFEbody) that is designed to reduce systemic toxicity to provide a potentially better safety profile. The company will update data on efficacy and tolerability results at the...
Valerii Apetroaiei/iStock via Getty Images Adagene Inc. ( ADAG ) is a clinical-stage oncology biotech that develops antibody-based immunotherapies. ADAG’s main asset is ADG126 (muzastotug), which uses its masking technology (SAFEbody) that is designed to reduce systemic toxicity to provide a potentially better safety profile. The company will update data on efficacy and tolerability results at the upcoming American Association for Cancer Research Annual Meeting 2026 (AACR 2026). ADAG also collaborates with Sanofi ( SNY ) and Incyte ( INCY ), which support ADG126’s R&D as well. Sanofi has committed up to $25 million for its Phase 2 in MSS CRC. ADAG will supply ADG126 for another SNY study evaluating the drug in advanced solid tumors. As such, I believe ADAG’s underlying science with ADG126 and compelling valuation warrant a speculative “Buy” rating for long-term investors at these levels. ADG126: Novel Immuno-Oncology Bet Adagene Inc. is a clinical-stage biotechnology company that develops cancer immunotherapies based on antibodies. ADAG was incorporated in the Cayman Islands back in 2011. It's the parent company of a subsidiary, Adagene Incorporated, registered in Delaware in 2017. However, the business itself is headquartered in Suzhou, Jiangsu Province, China. Interestingly, the ADSs have appreciated by about 150% from their 2026 lows, which is why I thought it was worthwhile covering this name. Source: Seeking Alpha. As a quick overview, ADAG’s pipeline includes its main asset, ADG126 , also called muzastotug. This is a masked antibody, which is studied in Phase 2 for microsatellite-stable colorectal cancer (MSS CRC) in patients without current or active liver metastases in combination with Keytruda, which is produced by Merck ( MRK ). A masked antibody is designed to stay inactive until it reaches the tumor environment, where certain enzymes remove the mask and activate it. Moreover, ADG126 targets CTLA-4 , an immune checkpoint that restrains T-cell activation, ...